Search results
Results from the Tech24 Deals Content Network
Viking Therapeutics is gearing up to compete with market GLP-1 leaders Novo Nordisk and Eli Lilly. ... Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma ...
Keith Speights, The Motley Fool. July 25, 2024 at 12:03 PM. Shares of Viking Therapeutics (NASDAQ: VKTX) were skyrocketing 32.3% as of 11:21 a.m. ET on Thursday. The big gain came after the ...
The much-feted biotech Viking Therapeutics (NASDAQ: VKTX) is aiming for Novo Nordisk's (NYSE: NVO) cash cow, the market for weight loss drugs. If its ambitions are fulfilled, it has a shot at ...
Viking Therapeutics is the center of attention after doubling estimated weight-loss rates in a recent drug trial. ... ," BTIG analyst Justin Zelin told Yahoo Finance Live. "So [Lilly] saw about a ...
According to a forecast by Goldman Sachs Research, the global weight loss drug market may multiply by a factor of 16 to reach $100 billion by the end of the decade. Today, Eli Lilly and Novo ...
Viking is one of the more promising among the many, many drugmakers trying to join the anti-obesity market and challenge Eli Lilly and Novo Nordisk (NYSE: NVO). The biotech does have another ...
Viking Therapeutics is the center of attention after doubling estimated weight loss rates in new drug trials. ... BTIG analyst Justin Zelin told Yahoo Finance. “So they saw about a 7% weight ...
Here's Why You Should Buy It. Alex Carchidi, The Motley Fool. July 29, 2024 at 8:45 AM. Viking Therapeutics (NASDAQ: VKTX) just gave shareholders a few more reasons to be excited for the future ...